Maternal T Cell Engraftment in SCID
Also known as: STR-SCID
Use
The Maternal T Cell Engraftment in SCID test is used to monitor the presence and proportion of maternal T cells in patients with severe combined immunodeficiency (SCID) prior to allogenic stem cell transplantation. SCID patients lack T cells, which can lead to complications such as graft-versus-host disease and difficulties in determining host T cell numbers necessary for diagnosis and treatment. This test helps in understanding the engraftment dynamics of maternal T cells, which can proliferate in the absence of host T cells.
Special Instructions
Not provided.
Limitations
Diagnostic errors may occur due to rare sequence variations. The limit of detection for this test is 2 percent of the minor cell population present in the specimen. The test has not been cleared or approved by the U.S. Food and Drug Administration but is performed in a CLIA-certified laboratory and intended for clinical use.
Methodology
PCR-based (Fragment Analysis)
Biomarkers
No genes
Gene
Result Turnaround Time
5-9 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
2 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A)
Storage Instructions
Ambient. Also acceptable: refrigerated. Ship overnight.
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 72 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant